Alivus Life Sciences Reports Robust Q2 FY26 Performance with 16% Revenue Growth and Margin Expansion

Alivus Life Sciences Limited , a leading developer and manufacturer of high-value Active Pharmaceutical Ingredients (APIs), has announced strong financial results for the second quarter of fiscal year 2026, demonstrating significant growth and improved profitability.

Key Financial Highlights

Metric	Q2 FY26	Q2 FY25	YoY Change
Revenue	₹5,880.00 Mn	₹5,069.00 Mn	16.0%
EBITDA	₹1,939.00 Mn	₹1,429.00 Mn	35.7%
EBITDA Margin	33.0%	28.2%	480 bps
PAT	₹1,301.00 Mn	₹953.00 Mn	36.5%
PAT Margin	22.1%	18.8%	330 bps

Revenue Growth and Market Expansion

Alivus Life Sciences reported a robust revenue growth of 16% year-over-year for Q2 FY26, with revenue from operations reaching ₹5,880.00 million. This growth was primarily driven by strong momentum in the non-GPL (Glenmark Pharmaceuticals Limited) business, which delivered an impressive 39.7% YoY growth.

The company's performance was bolstered by healthy demand across key geographies, including Rest of World (ROW), Latin America, Japan, Europe, and India. These markets contributed significantly to the overall performance, showcasing Alivus's successful market expansion strategy.

Profitability Improvement

Alivus demonstrated substantial improvement in its profitability metrics:

EBITDA grew by 35.7% YoY to ₹1,939.00 million
EBITDA margin expanded by 480 basis points to 33.0%
Profit After Tax (PAT) increased by 36.5% YoY to ₹1,301.00 million
PAT margin improved by 330 basis points to 22.1%

The company maintained its margins above the guided ranges, even without the benefits of the Production Linked Incentive (PLI) scheme, reflecting the robustness of its operations.

Operational Highlights and Future Outlook

Dr. Yasir Rawjee, MD & CEO of Alivus Life Sciences, expressed confidence in delivering stronger performance in the second half of the fiscal year. This optimism is supported by:

Continued robustness in the non-GPL business
Better visibility on the GPL business
Ongoing ramp-up of CDMO (Contract Development and Manufacturing Organization) projects

The company remains confident in maintaining margins around 30%, supported by a robust pipeline of new launches and operational efficiencies.

Financial Position

Alivus Life Sciences maintains a strong financial position:

Generated strong cash flow from operations of ₹148.00 crores in Q2 FY26
Cash and cash equivalents of ₹653.00 crores as of September 30, 2025
Debt-free balance sheet

The company's solid financial standing provides ample support for its ongoing growth plans.

Conclusion

Alivus Life Sciences' Q2 FY26 results demonstrate the company's ability to drive growth and improve profitability in the competitive API market. With its focus on high-value, non-commoditized APIs and expanding CDMO services, Alivus is well-positioned to capitalize on opportunities in the global pharmaceutical industry.

Investors and stakeholders can look forward to the company's continued performance in the second half of the fiscal year, supported by its strong product pipeline, operational efficiencies, and robust financial position.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-1.49%	-1.92%	-4.59%	-19.85%	-18.90%	+18.97%

Alivus Life Sciences Limited , a prominent player in the pharmaceutical industry, has been served a notice by the Gujarat Pollution Control Board (GPCB) imposing an interim Environment Damage Compensation of Rs 50 lakhs. This penalty comes in the wake of a flash fire incident that occurred at unit No. 6 of the company's Ankleshwar Plant on September 30, 2025.

Details of the Penalty

The GPCB's order, received by Alivus Life Sciences on October 18, 2025, outlines the following requirements:

Requirement	Amount (in Rs)
Immediate deposit	29,00,000
Bank guarantee	10,00,000
Total penalty	50,00,000

The company is mandated to immediately deposit Rs 29 lakhs as part of the interim Environment Damage Compensation. Additionally, Alivus Life Sciences is required to submit a bank guarantee of Rs 10 lakhs to ensure compliance, which will be considered at the time of revocation.

Company's Response

In its disclosure to the stock exchanges, Alivus Life Sciences stated that the incident and subsequent penalty are not expected to have a material impact on the company's financial position or operations. The company's management has indicated that the order is appealable, and they will assess the option of exercising their right to appeal.

Regulatory Compliance

This disclosure was made by Alivus Life Sciences in accordance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company's prompt disclosure demonstrates its commitment to regulatory compliance and transparency with its stakeholders.

Looking Ahead

As the situation unfolds, investors and stakeholders will be keenly watching how Alivus Life Sciences addresses this environmental concern and manages its impact on the company's operations. The company's decision regarding the appeal and any subsequent actions taken to prevent similar incidents in the future will be crucial factors in maintaining stakeholder confidence.

While the immediate financial impact may be limited, this incident underscores the importance of robust environmental and safety measures in the pharmaceutical manufacturing sector. It also highlights the increasing scrutiny and regulatory oversight that companies in this industry face regarding their environmental practices.